Patents by Inventor Xiaogang Shen
Xiaogang Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240089331Abstract: A display method includes obtaining P pieces of state information corresponding to P sessions in a communication application; and displaying P session identifiers corresponding to the P sessions on a first interface of the communication application according to the P pieces of state information. A display manner of each session identifier is associated with state information of a session corresponding to the session identifier. The state information of the session is used to represent a state of a chat dialogue in the session. The state information of the session includes first state information and second state information, the first state information is used to represent that the chat dialogue in the session is in an incomplete state, and the second state information is used to represent that the chat dialogue in the session is in a completed state. P is an integer greater than 1.Type: ApplicationFiled: November 17, 2023Publication date: March 14, 2024Inventor: Xiaogang Shen
-
Publication number: 20240024476Abstract: The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. For example, the compositions include CAR T cells comprising an extracellular domain that binds FCR1, MSLN, GPC-3, ALPP, CD70, CLDN6, ROR1, CD205, ACPP, ADAM12, or CLDN18.2.Type: ApplicationFiled: January 6, 2022Publication date: January 25, 2024Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Wensheng Wang, Beibei Jia, Dongqi Chen, Xiaoqiang Xu, Xudong Tang, Wei Ding, Xianyang Jiang, Yuzhe Peng, Guiting Han, Le Tian, Zhao Wu, Lei Xiao
-
Patent number: 11858977Abstract: Embodiments relate to a modified cell engineered to comprise a modified TCR-CD3 complex, wherein the CD3?, ?-chain, CD3?, and/or CD3? chains of the modified TCR-CD3 complex are linked to one or more co-stimulatory signaling domains.Type: GrantFiled: October 22, 2020Date of Patent: January 2, 2024Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Dongqi Chen, Xiaogang Shen
-
Patent number: 11788072Abstract: Embodiments relate to compositions and methods for treating solid tumors. For example, the compositions comprise modified cells comprising an isolated polynucleotide comprising a polynucleotide encoding a nuclear factor of activated T cells (NFAT) promoter operatively associated with a polynucleotide encoding FLT3L.Type: GrantFiled: April 29, 2020Date of Patent: October 17, 2023Assignee: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Chengfei Pu, Lei Xiao, He Sun, Xiaogang Shen, Cheng Lu
-
Publication number: 20230322899Abstract: The present disclosure relates to a fusion protein and uses thereof. For example, the fusion protein comprises an extra-cellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is derived from a first molecule, and the intracellular domain is derived from a second molecule. The first molecule is different from the second molecule, and the second molecule comprises OX40, CD40, 4-1 BB, GITR, ICOS, CD28, CD27, HER2, EGFR, EL-10R, IL-12R, IL-18R1, IL-23R, GP130, or IL-15Ra.Type: ApplicationFiled: August 24, 2021Publication date: October 12, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Xiaogang Shen, Zhiyuan Cao, Lei Xiao, Beibei Jia, Le Tian
-
Publication number: 20230293691Abstract: The present disclosure relates to compositions and methods for treating a subject having cancer associated with melanoma-associated antigen 4 (MAGE-A4) peptide. The disclosure includes the embodiments relate to a chimeric antigen receptor (CAR) that binds MAGE-A4 peptide, a polynucleotide encoding a CAR that binds the MAGE-A4 peptide, a modified cell comprising a CAR that binds the MAGE-A4 peptide, and a population of modified cells comprising a CAR that binds the MAGE-A4 peptide.Type: ApplicationFiled: June 9, 2021Publication date: September 21, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Chengfei Pu, Zhiyuan Cao, Xiaogang Shen, Dongqi Chen, Beibei Jia, Le Tian
-
Publication number: 20230227779Abstract: Embodiments of the present disclosure relate to compositions and methods of enhancing lymphocytes' ability to treat cancer patients. Embodiments relate to a polynucleotide comprising a nucleic acid encoding a chimeric antigen receptor (CAR), a nucleic acid encoding an Oxygen-Dependent Degradation domain (ODD), and a nucleic acid encoding one or multiple sequences of Hypoxia-Response Element (HRE).Type: ApplicationFiled: January 19, 2023Publication date: July 20, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Xiaogang Shen, Xudong Tang, Chengfei Pu, Lei Xiao, Le Tian
-
Publication number: 20230201440Abstract: The present disclosure relates to a system for immune therapy, the system comprising a sample processing module configured to obtain whole blood from a subject; a cell incubation module configured to activate blood cells of the whole blood and/or introduce a vector into the blood cells of the whole blood; and a cell infusion module configured to infuse at least a portion of the whole blood to the subject, wherein the blood cells comprise CD3+ cells, NK cells, myeloid cells, and neutrophils.Type: ApplicationFiled: May 7, 2021Publication date: June 29, 2023Inventors: Lei Xiao, Zhiyuan Cao, Zhao Wu, Chengfei PU, Xiaogang Shen, Haiyang Tang, Le Tian
-
Publication number: 20230201258Abstract: The present disclosure relates to compositions and methods for enhancing cell response and/or expanding chimeric antigen receptor (CAR) cells and/or maintenance in vivo and/or in vitro. In embodiments, the method comprises obtaining CAR T cells comprising a CAR comprising a binding domain that binds a solid tumor antigen, a transmembrane domain, and an intracellular domain; and contacting the CART cells with white blood cells and a bispecific antibody, such as a Bispecific T cell engager (BiTEĀ®), thereby activating the CAR T cells, wherein the level of activation of the CAR T cells is higher than the level of activation of CAR T ells that are contacted with B cells without the bispecific antibody. The bispecific antibody comprises a first binding domain binding CD3 and a second binding domain binding CD19, CD20, CD22, or BCMA.Type: ApplicationFiled: April 21, 2021Publication date: June 29, 2023Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Lei Xiao, Jingrui Liu, Junkai Peng, Le Tian, Xiaogang Shen, Zhiyuan Cao, Zhao Wu
-
Publication number: 20210371492Abstract: The present disclosure relates to compositions and methods of treating a subject having digestive tract cancer, the method comprising: administering an effective amount of a composition to the subject, the composition comprising a first population of cells comprising a first CAR binding a first antigen, and a second population of cells comprising a second CAR binding GCC, wherein the first antigen comprises a cell surface molecule of a white blood cell (WBC).Type: ApplicationFiled: May 26, 2021Publication date: December 2, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Xiaogang Shen, Wensheng Wang, Dongqi Chen, Beibei Jia, Chengfei Pu, Le Tian
-
Publication number: 20210122802Abstract: Embodiments relate to a modified cell engineered to comprise a modified TCR-CD3 complex, wherein the CD3?, ?-chain, CD3?, and/or CD3? chains of the modified TCR-CD3 complex are linked to one or more co-stimulatory signaling domains.Type: ApplicationFiled: October 22, 2020Publication date: April 29, 2021Applicants: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Chengfei Pu, Dongqi Chen, Xiaogang Shen
-
Publication number: 20200347367Abstract: Embodiments relate to compositions and methods for treating solid tumors. For example, the compositions comprise modified cells comprising an isolated polynucleotide comprising a polynucleotide encoding a nuclear factor of activated T cells (NFAT) promoter operatively associated with a polynucleotide encoding FLT3L.Type: ApplicationFiled: April 29, 2020Publication date: November 5, 2020Applicant: Innovative Cellular Therapeutics Holdings, Ltd.Inventors: Chengfei Pu, Lei Xiao, He Sun, Xiaogang Shen, Cheng Lu